Calvano Jacqueline E, Bowers Daniel J, Coyle Susette M, Macor Marie, Reddell Michael T, Kumar Ashwini, Calvano Steve E, Lowry Stephen F
Division of Surgical Sciences, Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, CAB 7300, 125 Paterson Street, New Brunswick, NJ 08903, USA.
Clin Immunol. 2006 Nov;121(2):186-90. doi: 10.1016/j.clim.2006.05.012. Epub 2006 Jul 7.
Mutations (Asp299Gly and Thr399Ile) in the human Toll-like receptor 4 (hTLR4) gene are reportedly associated with hyporesponsiveness to inhaled LPS in humans. It was hypothesized that normal volunteers with these hTLR4 mutations would manifest altered physiological responses to intravenous LPS administration. Human subjects (n = 57) were administered LPS (2 ng/kg) intravenously and monitored for vital signs (temperature, heart rate, mean arterial pressure). Blood-derived genomic DNA samples were evaluated using PCR to detect hTLR4 and TLR2 mutations. Heterozygous hTLR4 mutations were identified in 8 of the 57 subjects studied. Subjects with hTLR4 mutations demonstrated similar responses to LPS administration. The moderate systemic inflammatory response produced by intravenous LPS administration in human subjects is not modulated by the presence of heterozygous mutations in the hTLR4 gene.
据报道,人类Toll样受体4(hTLR4)基因中的突变(Asp299Gly和Thr399Ile)与人类对吸入性脂多糖(LPS)反应低下有关。有假设认为,携带这些hTLR4突变的正常志愿者对静脉注射LPS会表现出生理反应改变。对57名人类受试者静脉注射LPS(2 ng/kg),并监测生命体征(体温、心率、平均动脉压)。使用聚合酶链反应(PCR)评估血液来源的基因组DNA样本,以检测hTLR4和TLR2突变。在所研究的57名受试者中,有8名鉴定出杂合性hTLR4突变。携带hTLR4突变的受试者对LPS给药表现出相似的反应。hTLR4基因中杂合突变的存在不会调节人类受试者静脉注射LPS所产生的中度全身炎症反应。